

SCIENTIFIC PROGRAMME

09.00 – 10.30

Room: Chefren A

S1: Blood Donor Characteristics*Moderators: S. Diagneault, R. Reddy*

09.00 – 09.30

2A-S01-01 CHALLENGES IN ACHIEVING 100% VOLUNTARY BLOOD DONATION*G. Gabra (ISBT ATMC Coordinator, Birmingham, United Kingdom)*

09.30 – 09.45

2A-S01-02 THE 'RESTLESS LEGS SINDROM': FIRST DATA OF A RESEARCH AMONG OUR DONORS*C. Nocera, G.M. Leonardi, G. Di Domenico, M. D'Onofrio, L. Paesano, (P.O. San Giovanni Bosco, Napoli, Italy)*

09.45 – 10.00

2A-S01-03 COMPARATIVE STUDY OF VOLUNTARY AND FAMILY REPLACEMENT BLOOD DONORS: SAFETY AND PROFILE*H. Nasr, F. Mofteh (Egyptian National Transfusion Service, Cairo, Egypt)*

10.00 – 10.15

2A-S01-04 UNIVERSITY STUDENTS AND BLOOD DONATION*R. Grubovic, M. Grubovic, R. Dukovski, M. Blagoevska, S. Kostovska, G. Andonov, T. Makarovska, E. Velkova (National Institute for Transfusion Medicine, Skopje, Macedonia)*

10.15 – 10.30

2A-S01-05 DONORS 'AND NON-DONORS' DISTANCE FROM VOLUNTARY BLOOD DONATION*I. Petrovic (University of Belgrade, Faculty of Philosophy, Belgrade, Serbia)*

SCIENTIFIC PROGRAMME

09.00 – 10.30

Room: Chefren B

S2: Fetal-Maternal Immunology and Transfusion

Moderators: *E. Muñiz-Diaz, El Beshlawy*

09.00 – 09.30

2A-S02-01 MECHANISMS OF MATERNAL IMMUNISATION BY FETAL ANTIGENS

A. Husebekk (University of Tromsø, Tromsø, Norway)

09.30 – 09.45

2A-S02-02 THE FREQUENCY OF HPA-15 GENOTYPES IN POLISH POPULATION AND THE DETECTION OF HPA-15 ANTIBODIES IN FETAL/ NEONATAL ALLOIMMUNE THROMBOCYTOPENIA AND IN PATIENTS WITH PLATELET REFRACTORINESS

H. Michur, K. Guz, K. Maslanka, M. Uhrynowska, A. Misiak, A. Ejduk, E. Brojer (Institute of Haematology and Transfusion Medicine, Warsaw, Poland)

09.45 – 10.00

2A-S02-03 BLOCKADE OF MATERNAL ANTI-HPA-1A-MEDIATED PLATELET CLEARANCE BY AN HPA-1A EPITOPE-SPECIFIC F(AB)₂ IN AN IN VIVO MOUSE MODEL OF ALLOIMMUNE THROMBOCYTOPENIA

T.B. Bakchoul, B.B. Boylan, U.J.H. Sachs, G. Bein, C. Ruan, S. Santoso, P.J. Newman (Institute for Clinical Immunology and Transfusion Medicine, Giessen, Germany)

10.00 – 10.15

2A-S02-04 KUWAIT NATIONAL ANTENATAL PROGRAM FOR RED CELL TYPING AND ANTIBODY SCREENING: 5 YEARS STUDY

R. Al Radwan, H. Boules, R. Al Attar, B. Al Rayes, S. Shubbar, M. Thowainy (Blood Transfusion Administration Services, Hawally, Kuwait)

10.15 – 10.30

2A-S02-05 EXCHANGE TRANSFUSIONS IN NEW-BORNS IN UPPSALA UNIVERSITY HOSPITAL 2001-MEDIO 2008

A.C. Norda, B. Persson, Å. Englund, K. Schneider, J. Säfwenberg, S. Nordén Lindeberg (Clin Imm & Transfusion Medicine, Uppsala, Sweden)

SCIENTIFIC PROGRAMME

09.00 – 10.30

Room: Cheops

S3: Haemovigilance*Moderators: S. Hindawi, J.C. Faber*

09.00 – 09.30

2A-S03-01 HAEMOVIGILANCE: RECENT ACHIEVEMENTS AND DEVELOPMENTS IN THE NEAR FUTURE*R.R.P. de Vries (Leiden University Medical Center, Leiden, The Netherlands)*

09.30 – 09.45

2A-S03-02 THE CANADIAN TRANSFUSION ERROR SURVEILLANCE SYSTEM (TESS): RESULTS FROM A THREE-YEAR PILOT PROJECT*P. Robillard, J.L. Callum, C. Hyson (Institut National de Santé Publique du Québec, Montréal, Canada)*

09.45 – 10.00

2A-S03-03 INCORRECT BLOOD COMPONENTS TRANSFUSED IN AN ACADEMIC TRANSFUSION SERVICE IN THE LAST EIGHT YEARS*N. Carpio, F. Moscardó, I. Vaquero, F. Arriaga, M.A. Sanz (Hospital la Fe, Valencia, Spain)*

10.00 – 10.15

2A-S03-04 THE RESULTS OF LOOK BACK AND TRACE BACK PROCEDURES FOR HBV DNA POSITIVE/HBSAG NEGATIVE DONORS IDENTIFIED IN POLAND*A. Kopacz, P. Grabarczyk, E. Sulkowska, M. Letowska, E. Brojer (Institute of Haematology and Transfusion Medicine, Warsaw, Poland)*

10.15 – 10.30

2A-S03-05 HAEMOVIGILANCE IN NORDIC COUNTRIES: REPORT OF ADVERSE TRANSFUSION EVENTS 2007*M. Palfi, M.-K. Auvinen, E. Taaning, C. Steinsvåg, T. Jonsson (Clinical Immunology & Transfusion Medicine, Linköping, Sweden)*

SCIENTIFIC PROGRAMME

09.00 – 10.30

Room: Mlycerinos

S4: Updates on Hepatitis B (HBV)

Moderators: C. Velati, S. Wendel

09.00 – 10.30

2A-S04-01 HBV INFECTION IN THE MEDITERRANEAN BASIN AND EUROPE

J.P. Allain (University of Cambridge, Cambridge, United Kingdom)

09.00 – 10.30

2A-S04-02 HEPATITIS B VIRUS DNA AND SURFACE ANTIGEN PARTICLE CONCENTRATIONS IN EGYPTIAN BLOOD DONORS: LIMITS OF DETECTION OF ULTRA-SENSITIVE NUCLEIC ACID SCREENING TESTS IN HBSAG CARRIERS

M. El Ekiaby, J.P. Allain, J. Linnen, N.L. Lelie (Shabrawishi hospital, Cairo, Egypt)

09.00 – 10.30

2A-S04-03 POLYMORPHISM OF HEPATITIS B VIRUS FROM FIRST TIME BLOOD DONORS WITH HBSAG IN POLAND

E. Brojer, P. Grabarczyk, P. Garmiri, J.-P. Allain, Regional Blood Transfusion (Institute of Haematology and Transfusion Medicine, Warsaw, Poland)

09.00 – 10.30

2A-S04-04 A NEW HEPATITIS B VIRUS SUBTYPE D6 IN TUNISIAN BLOOD DONORS

B.H.M. Meldal, N.M. Mojaat, I. Barnes, K. Boukef, J.P. Allain (University of Cambridge, Cambridge, United Kingdom)

09.00 – 10.30

2A-S04-05 OCCULT HEPATITIS B INFECTION IN BLOOD DONORS: A REAL PROBLEM

M.I. Gonzalez Fraile, A.I. Jimenez del Bianco, E. Golvano Guerrero, F.V. Padron Rivas, L. Blanco Peris (Centro de Hemoterapia y Hemodonación de Castilla y León, Valladolid, Spain)

10.30 – 11.00

COFFEE AND TEA BREAK

SCIENTIFIC PROGRAMME

11.00 – 12.30

Room: Cheops

PL1-3: Controversies

Moderator: P Strengers

11.00 – 11.30

2B-PL1 DONORS HAVE NO RIGHTS?

B. O'Mahony (Irish Haemophilia Society Ltd., Dublin, Ireland)

11.30 – 12.00

2B-PL2 SAFETY HAS NO PRICE?

M. Contreras (National Blood Service, London, United Kingdom)

12.00 – 12.30

2B-PL3 BLOOD IS A GLOBAL COMMODITY?

A. Macmillan Douglas (Douglas Gorham Partnership Ltd., Brighton, United Kingdom)

12.30 – 14.30

LUNCH BREAK AND SATELLITE SYMPOSIA

SATELLITE SYMPOSIA

SATELLITE SYMPOSIUM

12.30 – 14.30

Room: **Chefren A**

Satellite Symposium organised by Roche

Increasing the Safety of Donated Blood by NAT Testing: Performance of the Roche Automated cobas s 201 System with the Multiplex NAT Test

This symposium focuses on the rapid progress made worldwide in increasing the safety of blood for transfusion by the introduction of nucleic acid amplification technology (NAT) into routine testing at blood banks. NAT testing identifies window period donations which are missed by serological testing. In addition, NAT testing has identified occult HBV infections which are missed by HBsAg testing. The greatest benefit of NAT testing is the identification of HCV window cases due to the very long window period of this virus compared with HBV and HIV-1. Following a brief discussion on HCV and NAT testing, the talks will summarize the experiences of NAT testing in Europe using the Roche automated NAT testing platform, the cobas s 201 system with the multiplexed cobas TaqScreen MPX test, which simultaneously detects the presence of HBV, HCV, HIV-1 Groups M and O, and HIV-2. The merits of an automated, multiplex test over the first generation manual tests will be discussed, as well as the challenges of introducing NAT testing into a blood screening environment. The speakers at this symposium include:

- **DR. D. PRATI**
Director, Dept. of Transfusion Medicine and Hematology, Ospedale Alessandro Manzoni, Lecco, Italy, Secretary of the Italian Association for the Study of the Liver (AISF)
- **DR. L. BLANCO**
Director, Centro de Hemoterapia y Hemodonación de Castilla y León, Valladolid, Spain
- **ADDITIONAL SPEAKERS TO BE CONFIRMED**

SATELLITE SYMPOSIA

SATELLITE SYMPOSIUM

12.30 – 14.30

Room: **Chefren B**

Satellite Symposium organised by Fenwal

Automated collection, driving efficiency

Moderator: Dr Magdy El Ekiaby, Head of Shabrawishi Hospital BTC, Cairo, Egypt

12.30

■ **INTRODUCTION AND MODERATING**

12.45

■ **OPERATING WITH AUTOMATED COLLECTIONS AT CAIRO**

Dr Magdy El Ekiaby (Head of Shabrawishi Hospital BTC, Cairo, Egypt)

13.00

■ **USING ALYX, FROM OPTIMIZATION TO INNOVATION, OUR EXPERIENCE**

Dr Farzal Anwar (Medical Director - Blood Transfusion Services, Jeddah, Saudi Arabia)

13.20

■ **RECRUITING YOUNG DONORS FOR AUTOMATION**

Dr Richard J. Benjamin (Chief Medical Officer, American Red Cross, Washington, USA)

13.40

■ **VALIDATION OF AMICUS SOFTWARE 3.1 FOR GREATER EFFICIENCY**

Dr Walter Nussbaumer, University Clinic Blood Transfusion Center, Innsbruck, Austria

14.00

■ **QUESTIONS & ANSWERS**

Dr Magdy El Ekiaby (Head of Shabrawishi Hospital BTC, Cairo, Egypt)

14.15

■ **CONCLUSIONS**

SATELLITE SYMPOSIA

SATELLITE SYMPOSIUM

12.30 – 14.30

Room: Mycerinos

Satellite Symposium organised by Octapharma

“Plasma Safety: Meet the Expert”

Since the first cases of vCJD appeared, major concerns were raised on the possibility to transmit the disease with the infusion of plasma. Whether the concerns raised are founded or not is today still an open issue. This has led some regulatory authorities to ask for special measures to reduce the theoretical load of prions in all biopharmaceutical plasma derived products, including biopharmaceutical solvent-detergent plasma for transfusion. The symposium will present an extend update on plasma safety and the current trends on plasma transfusion therapy.

12.30 – 12.40

■ INTRODUCTION

Moderator: *Dr. G. Sandler*

12.40 – 13.00

■ THE RISK FOR TRANSMITTING PRION DISEASE BY BLOOD AND PLASMA PRODUCTS

Speaker: *Dr. R. Knight*

13.00 – 13.20

■ PATHOGEN INACTIVATION: THE DEFINITIVE SAFEGUARD FOR PLASMA

Speaker: *A Bailey*

13.20 – 13.40

■ NON-INFECTIOUS SERIOUS HAZARDS IN PLASMA TRANSFUSION

To be announced

13.40 – 13.55

■ OPTIMISING THE USE OF PLASMA IN FINLAND MOVING TO OCTAPLAS®

Speaker: *Dr. T. Krusius*

13.55 – 14.30

■ WRAP-UP / DISCUSSION

Moderator: *Dr. G. Sandler*

SCIENTIFIC PROGRAMME

51

14.30 – 16.00

Room: Chefren A

S5: Cost/Effectiveness in Blood Transfusion Services*Moderators: K. Boukef, B. Custer*

14.30 – 15.00

2C-S05-01 RISK ANALYSIS AS A TOOL FOR MAKING DECISIONS IN BLOOD SERVICES*C. van der Poel (Sanquin Blood Supply Foundation, Amsterdam, The Netherlands)*

15.00 – 15.15

2C-S05-02 USE OF QUALITY TOOLS AND STATISTICAL TECHNIQUES FOR THE RESEARCH AND MANAGEMENT OF DAILY PROBLEMS IN A DEPARTMENT OF BLOOD DONATION AND TRANSFUSION*N. Psychogyios, E. Bolonaki, E. Lydaki, E. Nikoloudi, E. Symvoulakis, A. Stavroulaki, S. Stefanatos, K. Fountouli (Hellenic Open University of Patras, Greece, Heraklion, Greece)*

15.15 – 15.30

2C-S05-03 RESULTS OF AN ERROR-RISK-MANAGEMENT REPORTING SYSTEM (ERMS) AT THE RED CROSS BLOOD DONOR SERVICE BADEN-WÜRTTEMBERG-HESSEN IN 2007*W. Sireis, S. Findhammer, T. Müller-Kuller, M. Müller, K. Koerner, A. Karl, M. Wiesneth, E. Seifried (DRK-Blutspendedienst Baden-Württemberg - Hessen, Frankfurt, Germany)*

15.30 – 15.45

2C-S05-04 ELIMINATION OF REDDISH FFP PROBLEM IN EGYPTIAN NATIONAL BLOOD TRANSFUSION SERVICES*Sh. Shabayek, F. Mofteh, A.A. Aly (Egyptian National Blood Transfusion Services, Cairo, Egypt)*

15.45 – 16.00

2C-S05-05 FMEA IN TRANSFUSION RISK MANAGEMENT: EXPERIENCE IN A HOSPITAL-BASED TRANSFUSION SERVICE*P. Bertj, M. Dujany, M. Marana, E. Viérin, A.R. Barbagelata (AUSL Valle d'Aosta, Aosta, Italy)*

SCIENTIFIC PROGRAMME

14.30 – 16.00

Room: Cheops

S6: TRALI versus TACO

Moderators: J. Wallis, P. Holland

14.30 – 15.00

2C-S06-01 TRANSFUSION-ASSOCIATED CIRCULATORY OVERLOAD AND TRANSFUSION-RELATED ACUTE LUNG INJURY: DIAGNOSIS, PATHOPHYSIOLOGY, MANAGEMENT AND PREVENTION

G. Andreu (Institut National de la Transfusion Sanguine, Paris, France)

15.00 – 15.15

2C-S06-02 OUTCOME AMONG RECIPIENTS OF PLASMA FROM FEMALE DONORS-A REGISTER-BASED COHORT STUDY

A.E. Shanwell, E. Tynell, R. Norda, T. Andersson, G. Edgren, M. Reilly (Karolinska University Hospital, Stockholm, Sweden)

15.15 – 15.30

2C-S06-03 AUTOMATISATION IN THE SCREENING FOR DETECTION OF GRANULOCYTE ANTIBODIES WITH A NOVEL ASSAY

X.D. Nguyen, F. Stötzer, B. Flesch, H. Kroll, H. Klüter (Institute of Transfusion Medicine and Immunology, Mannheim, Germany)

15.30 – 15.45

2C-S06-04 NT-PRO BNP AS A MARKER FOR DIFFERENTIAL DIAGNOSIS BETWEEN TRALI AND TACO

H. Okazaki, S. Hashimoto, F. Nakajima, K. Tadokoro (Japanese Red Cross Society, Tokyo, Japan)

15.45 – 16.00

2C-S06-05 TRANSFUSION-ASSOCIATED CIRCULATORY OVERLOAD (TACO): THE NEW NUMBER ONE KILLER REPORTED TO THE QUÉBEC HEMOVIGILANCE SYSTEM

P. Robillard, K.I. Nawej, A. Chapdelaine (Institut National de Santé Publique du Québec, Montréal, Canada)

SCIENTIFIC PROGRAMME

53

14.30 – 16.00

Room: Mycerinos

S7: Hereditary Bleeding Disorders

Moderators: A. Husebekk, E. Briët

14.30 – 15.00

2C-S07-01 MANAGEMENT OF MENORRHAGEA, NEW APPROACHES TO IMPROVE QUALITY OF LIFE AND REDUCTION OF TRANSFUSION NEEDS

A. Kadir (Royal Free Hospital, London, United Kingdom)

15.00 – 15.30

2C-S07-02 IMPACT OF GENETICS IN HEREDITARY BLEEDING DISORDERS

J. Oldenburg (University of Bonn, Bonn, Germany)

15.30 – 16.00

2C-S07-03 CURRENT STATUS OF RECOMBINANT FVIIA IN THE TREATMENT OF MASSIVE HAEMORRHAGE / TRAUMA

H. Goubran (National Blood Transfusion Services, Giza, Egypt)

SCIENTIFIC PROGRAMME

14.30 – 16.00

Room: Chefren B

S8: Updates on Hepatitis C (HCV)

Moderators: S. Sauleda, S. Stramer

14.30 – 15.00

2C-S08-01 HEPATITIS C INFECTION: RECENT INSIGHTS RELEVANT TO TRANSFUSION SAFETY

M. Busch, S.H. Kleinman (Blood Systems Research Institute, San Francisco, California, USA)

15.00 – 15.15

2C-S08-02 ESTIMATION OF THE RISK OF HEPATITIS C VIRUS INFECTIOUS DONATIONS ENTERING THE BLOOD SUPPLY IN SHANGHAI, 2006-2007

X. Wang, X. Zhang, X.M. Li, Y. Jia, L. Zheng, K.C. Qian, Y.M. Zhu (Shanghai Blood Center, Shanghai, China)

15.15 – 15.30

2C-S08-03 THE IMPACT OF DIFFERENT HCV BLOOD SCREENING TECHNOLOGIES ON THE REDUCTION OF TRANSFUSION TRANSMITTED HCV INFECTION RISK IN EGYPT

M. El Ekiaby, S. Laperche, F. Mofteh, T. Burnouf, N. Lelie (Shabrawishi Hospital, CAIRO, Egypt)

15.30 – 15.45

2C-S08-04 EVALUATION OF THE ARCHITECT HCV ANTIGEN ASSAY FOR USE IN ORGAN AND TISSUE DONORS

I. Mihaljevic (Croatian Institute of Transfusion Medicine, Zagreb, Croatia)

15.45 – 16.00

2C-S08-05 GROWTH AND REPLICATION OF PLASMA-DERIVED HEPATITIS C VIRUS IN CELL CULTURE

D. Taylor, E. Silberstein, L. Ulitzky, K. Mihalik, E. Plant, M. Puig, S.M. Feinstone (U.S. FDA, Bethesda, MD, USA)

16.00 – 16.30

COFFEE AND TEA BREAK

SCIENTIFIC PROGRAMME

16.30 – 18.00

Room: Chefren A

S9: Role of IT

Moderators: R. Knels, P. Bruce

16.30 – 17.00

2D-S09-01 BLOOD DONOR MANAGEMENT SYSTEM (BDMS)

J. Emmanuel, M. Mwafulirwa (Safe Blood for Africa (SBFA), Harare, Zimbabwe)

17.00 – 17.30

2D-S09-02 ROLE OF IT IN BLOOD TRANSFUSION MEDICINE

A. Macmillan Douglas (Douglas Gorham partnership Ltd., Brighton, United Kingdom)

17.30 – 17.40

2D-S09-03 DEVELOPING INTERFACE STANDARDS - FUTURE ISBT GUIDELINES

P. Ashford (ICCBBA, Rochester, United Kingdom)

17.40 – 17.50

2D-S09-04 VALIDATION OF AUTOMATED SYSTEMS IN BLOOD ESTABLISHMENTS-ISBT GUIDELINE

J. Sampson (Welsh Blood Service, Cardiff, United Kingdom)

17.50 – 18.00

2D-S09-05 RADIO FREQUENCY IDENTIFICATION (RFID) IN TRANSFUSION MEDICINE

R. Knels (German Red Cross Blood Donation Service East, Dresden, Germany)

SCIENTIFIC PROGRAMME

16.30 – 18.00

Room: Chefren B

S10: Rh Immunology

Moderators: G. Daniels, A. Kamel

16.30 – 17.00

2D-S10-01 RH IMMUNOLOGY

E. van der Schoot (Sanquin Blood Supply Foundation, Amsterdam, The Netherlands)

17.00 – 17.15

2D-S10-02 D ANTIGEN VARIANTS IN THE ITALIAN POPULATION: THE 'RAINBOW PROJECT'

A. Matteocci, A. Moscetti, S. Ferrari, A.L. Massaro (AO San Camillo-Forlanini, Roma, Italy)

17.15 – 17.30

2D-S10-03 SEROLOGICAL AND MOLECULAR CHARACTERIZATION OF D VARIANTS

M. Mota, D. Credidio, M. Dezan, M.G. Aravechia, J.M. Kutner, L. Castilho (Hospital Israelita Albert Einstein, São Paulo, Brazil)

17.30 – 17.45

2D-S10-04 RHD ANTIGEN EXPRESSION FROM THE CEAR ALLELE: AN RHD POSITIVE BLOOD DONOR NOT CARRYING THE DAR VARIANT USUALLY ASSOCIATED

N. Nogues, N. Boto, M. Ibanez, R. Montero, M. Tarrago, N. Casamitjana, M. Salgado, E. Farssac, C. Canals, E. Muniz-Diaz (Banc de Sang i Teixits, Barcelona, Spain)

17.45 – 18.00

2D-S10-05 MASS-SCALE GENOTYPING OF RBC DONORS IN THE BASQUE COUNTRY

M.A. Vesga, M. Azkarate, S. Santos, A. Renovales, M. Rubia, M. Sierra, M. Lopez, D. Tejedor, A. Martinez (Centro Vasco de Transfusiones y Tejidos Humanos, Bizkaia, Spain)

SCIENTIFIC PROGRAMME

16.30 – 18.00

Room: Mycerinos

S11: Blood Donation*Moderators: D. de Coning, M. El Alfy*

16.30 – 17.00

2D-S11-01 WHY DO PEOPLE GIVE BLOOD? STUDIES ON MOTIVATION FACTORS RELEVANT FOR RECRUITMENT AND RETENTION OF VOLUNTARY, NON-REMUNERATED BLOOD DONORS*A. Misje (University of Bergen, Bergen, Norway)*

17.00 – 17.15

2D-S11-02 BLOOD DONOR RECRUITMENT PROGRAM AT NATIONAL BLOOD TRANSFUSION SERVICES, EGYPT*G. Hamdalla, F. Moftah (National Blood Transfusion Services, Giza, Egypt)*

17.15 – 17.30

2D-S11-03 THE ROLE OF SCHOOL TEACHERS TO SUPPORT BLOOD COLLECTION AND DONOR RETENTION AT SCHOOLS*A.P.M. Los, G. Gabra, S. Mutegombwa, C.Th. Smit Sibinga (Academic Institute IDTM, Groningen, The Netherlands)*

17.30 – 17.45

2D-S11-04 THE SOCRATES COMENIUS PROJECT 'VOLUNTARY WORK-BLOOD DONATION' A TOOL FOR HEALTH EDUCATION IN SCHOOLS OF ROMANIA/TURKEY/GREECE - PROMOTION OF SOLIDARITY AND BLOOD DONATION IN STUDENTS AND CITIZENS*G. Martinis, T. Samidou, Ch. Tsigalou, A. Pricina, S. Tasova, Z. Bezirgiannidou, F. Sopasi, Ch. Boutziloudi (University Hospital of Alexandroupolis, Alexandroupolis, Greece)*

17.45 – 18.00

2D-S11-05 EVALUATION OF DONORS' SATISFACTION AS PART OF ANNUAL INTERNAL ASSESSMENT*G. Alkanderi, M. Hasan, W. Atta (Kuwait Central Blood Bank, Surra, Kuwait)*

SCIENTIFIC PROGRAMME

16.30 – 18.00

Room: Cheops

S12: Bacterial Contamination

Moderators: R. Benjamin, E. Wood

16.30 – 17.00

2D-S12-01 COMPARISON OF DIFFERENT METHODS OF BACTERIAL DETECTION IN BLOOD COMPONENTS

M. Schmidt (German Red Cross, Frankfurt am Main, Germany)

17.00 – 17.12

2D-S12-02 THE BACTERIAL CONTAMINATION OF PAEDIATRIC WHOLE BLOOD TRANSFUSIONS IN A KENYAN HOSPITAL

O. Hassall, K. Maitland, L. Pole, S. Mwarumba, D. Denje, K. Wambua, B. Lowe, C. Parry, K. Mandaliya, I. Bates (Kenya Medical Research Institute, Kilifi, Kenya)

17.12 – 17.24

2D-S12-03 EVALUATION OF THE BACT/ALERT AUTOMATED MICROBIAL DETECTION SYSTEM FOR THE SCREENING OF HAEMOPOIETIC PROGENITOR CELLS

C. McDonald, S. McGuane, J.G. Davis, S. Loaiza (National Blood Service, London, United Kingdom)

17.24 – 17.36

2D-S12-04 INTRODUCTION OF BACTERIAL SCREENING OF PLATELETS IN AUSTRALIA; MANAGING THE CLINICAL IMPACT

M. Borosak, J. Wong, P. Dennington, S. Winzar, E. Wood, J. Pink (Transfusion Medicine Service, South Melbourne, Australia)

17.36 – 17.48

2D-S12-05 AN OPTIMIZED REAL-TIME 16S RIBOSOMAL DNA POLYMERASE CHAIN REACTION ASSAY FOR BACTERIAL CONTAMINATION IN PLATELET CONCENTRATES

X. Liu (Shanghai blood center, Shanghai, China)

17.48 – 18.00

2D-S12-06 A LABORATORY COMPARISON OF MIRASOL® PATHOGEN REDUCTION TECHNOLOGY TREATMENT AND CULTURE OF PLATELET PRODUCTS FOR ADDRESSING BACTERIAL CONTAMINATION CONCERNS

R. Goodrich, S. Keil, D. Gilmour, N. Hovenga, M. Miklauz (CaridianBCT Biotechnologies, Lakewood, USA)

POSTER WALK

18.00 – 19.00

POSTER WALK (exhibition hall)

Poster-walks are going to be held again this year. This event was introduced in Cape Town in order to gain a maximum benefit from the scientific work presented and to create a lively interaction between poster authors, moderators and interested congress participants. On Monday, March 23, 2009 poster authors, moderators and interested congress participants are kindly requested to be present at the first poster in the poster session at the beginning of the presentation time at 18.00 hours.

Snacks and drinks will be served during the posterwalks

THE FOLLOWING POSTERS WILL BE DISCUSSED ON MONDAY

Topic

No's on display

Administrative

- | | | |
|--------------|--|-----------------------|
| 1.1 : | Blood Transfusion as an Integral Part of National Health System | P-001 – P-021 |
| 1.2 : | Role of IT | P-022 – P-027 |
| 1.3 : | Cost/Effectiveness in BTS Based on Risk Models and Risk Analysis | P-028 – P-034 |
| 1.4 : | Human Resources in Blood Banks | P-035 – P-039A |

TTI

- | | | |
|--------------|--|-----------------------|
| 2.1 : | Updates on Hepatitis B (HBV) | P-040 – P-066 |
| 2.2 : | Updates on Hepatitis C (HCV) | P-067 – P-084 |
| 2.3 : | Bacterial Contamination | P-085 – P-094 |
| 2.4 : | Parasites and Transfusion | P-095 – P-099A |
| 2.5 : | Infectious Diseases and Emerging Pathogens | P-100 – P-128 |

Blood Donation

- | | | |
|--------------|-----------------------------|----------------------|
| 3.1 : | Blood Donation | P-129 – P-159 |
| 3.2 : | Blood Donor Characteristics | P-160 – P-182 |
| 3.3 : | Donor Adverse Events | P-183 – P-192 |



POSTER WALK

Immune Haematology

- | | | |
|------------|---|----------------------|
| 4.1 | : Fetal-Maternal Immunology and Transfusion | P-193 – P-206 |
| 4.2 | : Platelet Immunology | P-207 – P-217 |
| 4.3 | : Red Cell Immunology | P-218 – P-276 |

Clinical Transfusion

- | | | |
|------------|--|----------------------|
| 5.1 | : Maternal Health and Blood Transfusion including Paediatric Transfusion | P-278 – P-283 |
| 5.2 | : (Therapeutic) Apheresis | P-284 – P-301 |
| 5.3 | : Evidence Based Transfusion Medicine | P-302 – P-321 |
| 5.4 | : Bed Side Transfusion | P-322 – P-323 |
| 5.5 | : Blood Utilization (NATA) | P-325 – P-341 |
| 5.6 | : TRALI and TACO | P-342 – P-347 |
| 5.7 | : Hereditary Bleeding Disorder | P-349 – P-350 |
| 5.8 | : Haemovigilance | P-351 – P-370 |

Blood Products

- | | | |
|------------|------------------------------|----------------------|
| 6.1 | : Rare Donor Programmes | P-371 – P-373 |
| 6.2 | : Plasma for fractionation | P-374 |
| 6.3 | : Pathogen Inactivation | P-375 – P-404 |
| 6.4 | : Blood Derived Biomaterials | P-406 – P-417 |

Transfusion Science

- | | | |
|------------|-------------------------------------|----------------------|
| 7.1 | : Alternatives to Blood Transfusion | P-418 – P-422 |
| 7.2 | : Innovations in Blood Transfusion | P-423 – P-454 |
| 7.3 | : Universal Blood | P-455 – P-456 |